This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Jacobio Pharmaceuticals Group Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Jacobio Pharmaceuticals Group's revenue is forecast to decline at 24.8% per annum.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum	41.8%
Wachstumsrate der Einnahmen	-24.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	31 Jan 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

SZSC:1167 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	60	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
12/31/2023	60	N/A	N/A	N/A	1
6/30/2023	81	-410	-449	-400	N/A
3/31/2023	89	-391	-379	-346	N/A
12/31/2022	96	-372	-309	-292	N/A
9/30/2022	123	-332	-230	-218	N/A
6/30/2022	150	-292	-151	-145	N/A
3/31/2022	151	-297	-155	-146	N/A
12/31/2021	153	-301	-159	-147	N/A
9/30/2021	348	-570	-70	-56	N/A
6/30/2021	544	-839	18	36	N/A
3/31/2021	515	-1,177	43	57	N/A
12/31/2020	486	-1,514	68	79	N/A
9/30/2020	243	-1,298	-37	-30	N/A
6/30/2020	N/A	-1,082	-141	-139	N/A
3/31/2020	N/A	-753	-129	-126	N/A
12/31/2019	N/A	-425	-116	-113	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if 1167's forecast earnings growth is above the savings rate (2%).

Ertrag vs. Markt: Insufficient data to determine if 1167's earnings are forecast to grow faster than the Hong Kong market

Hohe Wachstumserträge: Insufficient data to determine if 1167's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: 1167's revenue is expected to decline over the next 3 years (-24.8% per year).

Hohe Wachstumseinnahmen: 1167's revenue is forecast to decline over the next 3 years (-24.8% per year).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if 1167's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Jacobio Pharmaceuticals Group Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Jacobio Pharmaceuticals Group Co., Ltd. Presents the Pre-Clinical Data of Shp2 Inhibitorjab-3312 in Combination with Kras G12c Inhibitor Glecirasibat the Fifth Ras Initiative Symposium 2024

Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval from the U.S. FDA for Pan-KRAS Inhibitor JAB-23E73

Jacobio Pharmaceuticals Group Co., Ltd. Announces Board Changes

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dosing in the Phase III Clinical Trial of Glecirasib in Combination with Glecirasib

Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences an Equity Buyback Plan for 79,175,508 shares, representing 10% of its issued share capital, under the authorization approved on June 7, 2024.

Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer

Jacobio Pharma Announces Its KRAS G12C Inhibitor Reached the Primary Endpoint

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 07, 2024

Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors At the 2024 ASCO GI

New minor risk - Share price stability

Jacobio Pharmaceuticals Group Co., Ltd. Announces Clinical Results in the Oral Abstract Session of Clinical Oncology Gastrointestinal Cancers Symposium

Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with Jab-3312 At Esmo

Executive Chairman & CEO recently bought HK$594k worth of stock

First half 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.17 loss in 1H 2022)

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Jacobio Pharmaceuticals Group Co., Ltd.'S In-House KRAS G12C Inhibitor Jab-21822 (Glecirasib) Granted Breakthrough Therapy Designation for Pancreatic Cancer Patients

Jacobio Pharmaceuticals Group Co., Ltd. announced that it expects to receive CNY 150 million in funding from Beijing E-Town International Investment & Development Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd. Presents Clinical Results of Glecirasib in Colorectal Cancer

Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval for PARP7 Inhibitor JAB-26766 in China

Full year 2022 earnings released: CN¥0.49 loss per share (vs CN¥0.40 loss in FY 2021)

Jacobio Pharma Completes First Patient Dosage of Aurora Inhibitor JAB-2485 in U.S

Jacobio's Kras G12c Inhibitor JAB-21822 Was Granted Breakthrough Therapy Designations by China Cde

Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022

Less than half of directors are independent

Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China

Jacobio Pharma Completes First Patient Dosage of Cd73 Mab Jab-Bx102 in China

Jacobio Pharmaceuticals Group Co., Ltd. Announces First Patient Dosed with JAB-21822 in the Phase IIa Trial on KRAS G12C and STK11 Co-Mutation

Jacobio Pharmaceuticals Group Co., Ltd. Announces Change of Joint Company Secretary

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2022 Results on Aug 23, 2022

Jacobio Pharma will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting

Less than half of directors are independent

Senior VP & Executive Director recently bought HK$150k worth of stock

Senior VP & Executive Director recently bought HK$336k worth of stock

Jacobio Pharmaceuticals Group Co., Ltd. JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China

Senior VP & Executive Director recently bought HK$1.6m worth of stock

Jacobio Pharmaceuticals Group Co., Ltd. Announces Investigational New Drug Approval of Aurora A Inhibitor JAB-2485 from Food and Drug Administration of the United States

Jacobio Pharma Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China

Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of Kras G12c Inhibitor for Solid Tumor

Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering $20 Million Milestone Payment

Jacobio Announces FDA Approves IND Application to Develop KRAS G12c Inhibitor

Joint Company Secretary has left the company

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken